Presidential aspirant Francisco “Isko Moreno” Domagoso wants to include President Rodrigo Duterte on the list of those he will support in the 2022 senate under his ticket – despite the tension between them in the past two months.
Just this year, Digong accused a Metro Manila mayor of being a porn star who he said he wanted to remove from the power to distribute lockdown aid due to the “chaotic” vaccination against COVID-19. Domagoso was the only Metro Manila mayor who used to be a sexy star because of his previous career in showbiz.
“I will personally vote for Duterte as senator. Given his track record and accomplishments as president, he is very capable for that position,” Domagoso said in a social media post, Monday.
“Ayaw ko siyang pangunahan but I would be humbled and honored to have him in our slate.”
Domagoso said he is involved in the administration’s Build Build Build infrastructure program, in addition to its vaccination program against COVID-19.
He said this during his tour in Lapu-Lapu City today, even though his Aksyon Demokratiko party had slapped Digong for “politicking” him in distributing aid.
Isko Moreno now wants to include Duterte on his 2022 senatorial slate
It was only in September when the actor-turned-presidential bet said that he would face Digong when it was time to file his certificate of candidacy. However, the president will run for a different position – the senatorship.
It will be recalled that in August, Isko told Digong that their help was “efficient” after the president’s alleged attacks on him.
“Kung papayag si President Duterte maging guest candidate, I will be humbled and honored for him to be part of our slate,” Isko Moreno added.
“For the meantime, ayaw ko pangunahan si pangulo.”
The presidential bet has repeatedly said that he is “not” a “closet Duterte” candidate and that he can only cooperate with anyone, whether in the administration or the opposition.
He then lashed out at the administration while calling on it to prioritize purchasing the experimental COVID-19 drugs Tocilizumab and Remdesivir over the procurement of face shields.